[Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Minoru Miztani, Tomohiro Noda, Akira Umino, Motoaki Tanigawa, Masanori Taniguchi, Shigehisa Tamaki, Kouta Tsuji
Abstract
Minoru Miztani, Tomohiro Noda, Akira Umino, Motoaki Tanigawa, Masanori Taniguchi, Shigehisa Tamaki, Kouta Tsuji
Abstract
A 51-year-old woman, who presented with dyspnea on effort and was diagnosed with autoimmune hemolytic anemia in July 2004, was suspected of having splenic marginal zone lymphoma (SMZL) because of clonality of B cell on bone marrow and splenomegaly. She underwent splenectomy, and histopathological examination of the resected specimen confirmed the diagnosis of SMZL. The patient was treated with rituximab, and complete remission was achieved. Up to the present, three years after diagnosis, the patient has shown no evidence of progression.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A 51-year-old woman, who presented with dyspnea on effort and was diagnosed with autoimmune hemolytic anemia in July 2004, was suspected of having splenic marginal zone lymphoma (SMZL) because of clonality of B cell on bone marrow and splenomegaly. She underwent splenectomy, and histopathological examination of the resected specimen confirmed the diagnosis of SMZL. The patient was treated with rituximab, and complete remission was achieved. Up to the present, three years after diagnosis, the patient has shown no evidence of progression.
Key concepts: Medicine, Splenic marginal zone lymphoma, Splenectomy, Autoimmune hemolytic anemia, Rituximab, Lymphoma, Anemia, Hemolytic anemia